MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced the formation of a steering committee for the Company’s Phase 3 LEVO-CTS trial to evaluate levosimendan in cardiac surgery patients at risk of developing low cardiac output syndrome (LCOS). The committee includes experts in the fields of cardiology, cardiac surgery, cardiac anesthesia and clinical trials.
Help employers find you! Check out all the jobs and post your resume.
